Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
110 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Community Acquired Pneumonia - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Community Acquired Pneumonia - Pipeline Review, H1 2016', provides an overview of the Community Acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia - The report reviews pipeline therapeutics for Community Acquired Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Community Acquired Pneumonia therapeutics and enlists all their major and minor projects - The report assesses Community Acquired Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Community Acquired Pneumonia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Community Acquired Pneumonia Overview 8 Therapeutics Development 9 Pipeline Products for Community Acquired Pneumonia - Overview 9 Community Acquired Pneumonia - Therapeutics under Development by Companies 10 Community Acquired Pneumonia - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Community Acquired Pneumonia - Products under Development by Companies 14 Community Acquired Pneumonia - Companies Involved in Therapeutics Development 15 AstraZeneca Plc 15 BioAegis Therapeutics, Inc. 16 Biotest AG 17 C10 Pharma AS 18 ioGenetics, Inc. 19 Kyorin Pharmaceutical Co., Ltd. 20 Melinta Therapeutics, Inc 21 Merck & Co., Inc. 22 Nabriva Therapeutics AG 23 Paratek Pharmaceuticals, Inc. 24 TaiGen Biotechnology Co., Ltd. 25 Takeda Pharmaceutical Company Limited 26 Tetraphase Pharmaceuticals Inc. 27 Community Acquired Pneumonia - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 BT-086 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 C-10 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 ceftaroline fosamil - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 DBAF-301 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 delafloxacin - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 KRPAM-1977X - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 lefamulin acetate - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 nemonoxacin - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 omadacycline tosylate - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 PneumoMab - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 radezolid - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Recombinat Protein to Replace Plasma Gelsolin for Community Acquired Pneumonia - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 solithromycin - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 ticagrelor - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 TP-271 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 TP-834 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Community Acquired Pneumonia - Recent Pipeline Updates 71 Community Acquired Pneumonia - Dormant Projects 98 Community Acquired Pneumonia - Discontinued Products 99 Community Acquired Pneumonia - Product Development Milestones 100 Featured News & Press Releases 100 Feb 05, 2016: The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra Oral Solithromycin in Community-Acquired Bacterial Pneumonia 100 Feb 01, 2016: Cempra and Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement for Solithromycin 100 Jan 06, 2016: Melinta Therapeutics Initiates Phase 3 Study of Baxdela in Hospital-Treated Community-Acquired Bacterial Pneumonia 101 Dec 22, 2015: Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents 102 Dec 03, 2015: TaiGen's Intravenous Taigexyn Successfully Achieved Primary Endpoint in Phase 3 Clinical Trial for Community Acquired Pneumonia 103 Nov 09, 2015: Paratek Initiates Omadacycline Phase 3 Clinical Study in Community Acquired Bacterial Pneumonia 103 Nov 04, 2015: Paratek Receives FDA Fast Track Designation for Omadacycline 103 Oct 23, 2015: Cempra to Present Solithromycin Oral Data at CHEST 2015 104 Oct 16, 2015: Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia 105 Oct 13, 2015: Nabriva Presents Data on Lefamulin at the 2015 ID Week in San Diego 107 Appendix 109 Methodology 109 Coverage 109 Secondary Research 109 Primary Research 109 Expert Panel Validation 109 Contact Us 109 Disclaimer 110
List of Tables
Number of Products under Development for Community Acquired Pneumonia, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Community Acquired Pneumonia - Pipeline by AstraZeneca Plc, H1 2016 15 Community Acquired Pneumonia - Pipeline by BioAegis Therapeutics, Inc., H1 2016 16 Community Acquired Pneumonia - Pipeline by Biotest AG, H1 2016 17 Community Acquired Pneumonia - Pipeline by C10 Pharma AS, H1 2016 18 Community Acquired Pneumonia - Pipeline by ioGenetics, Inc., H1 2016 19 Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 20 Community Acquired Pneumonia - Pipeline by Melinta Therapeutics, Inc, H1 2016 21 Community Acquired Pneumonia - Pipeline by Merck & Co., Inc., H1 2016 22 Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics AG, H1 2016 23 Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals, Inc., H1 2016 24 Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016 25 Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 26 Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 27 Assessment by Monotherapy Products, H1 2016 28 Number of Products by Stage and Target, H1 2016 30 Number of Products by Stage and Mechanism of Action, H1 2016 32 Number of Products by Stage and Route of Administration, H1 2016 34 Number of Products by Stage and Molecule Type, H1 2016 36 Community Acquired Pneumonia Therapeutics - Recent Pipeline Updates, H1 2016 71 Community Acquired Pneumonia - Dormant Projects, H1 2016 98 Community Acquired Pneumonia - Discontinued Products, H1 2016 99
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.